Bristol Myers Squibb (NYSE: BMY)
$61.08
(1.8%)
$1.06
Price as of March 31, 2025, 3:58 p.m. ET
BMY
Key Data Points
Current Price
$61.09
Daily Change
(1.8%) $1.07
Day's Range
$59.73 - $61.64
Previous Close
$60.99
Open
$59.80
Beta
0.34
Volume
11,616,280
Average Volume
11,682,846
Sector
Market Cap
$124B
Market Cap / Employee
$4M
52wk Range
$39.35 - $63.33
Revenue
$48B
Gross Margin
56.80%
Dividend Yield
4.0%
EPS
-$4.43
CAPs Rating
-
Industry
Pharmaceuticals
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Bristol Myers Squibb Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Bristol Myers Squibb Company Info
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
News & Analysis
The Fool has written over 500 articles on Bristol Myers Squibb.
Featured Article
Beat the S&P 500 With This Cash-Gushing Dividend Stock
Dan Victor | Apr 1, 2025
Featured Article
Is Bristol Myer Squibb's High-Yielding Dividend Safe?
David Jagielski | Mar 31, 2025
3 Deeply Discounted Dividend Stocks to Buy Today
David Jagielski | Mar 27, 2025
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Prosper Junior Bakiny | Feb 26, 2025
Bristol Myers Squibb Tops Q4 Estimates
JesterAI | Feb 6, 2025
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Prosper Junior Bakiny | Jan 31, 2025
3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
David Jagielski | Jan 29, 2025
This Unpopular Dividend Stock Is a Buy
George Budwell | Jan 9, 2025
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes

The Top Biotech Stocks to Watch Following ASH 2019
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
Todd Campbell | Dec 19, 2019

3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year
These stocks skyrocketed following exciting announcements.
Todd Campbell | Jan 10, 2019
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.